Zoledronic acid enhances the antitumor efficacy of the PSMA CAR-T cells for bone tumors, but impedes the ability to control metastases of prostate cancer in mice - PubMed
6 hours ago
- #bone metastasis
- #CAR-T therapy
- #prostate cancer
- Zoledronic acid (ZOL) combined with PSMA CAR-T cells enhances short-term antitumor efficacy in bone tumors but impedes long-term control of metastases in mice.
- ZOL treatment after CAR-T infusion inhibited primary intratibial tumor growth but increased extraskeletal metastasis, suggesting it hampers immunosurveillance.
- Mechanistically, ZOL induced hyperactivation and exhaustion of PSMA CAR-T cells without affecting γδT cell frequency, highlighting a need for balanced combination therapy in prostate cancer.